Sign in

James Mullen

American businessperson and board member; Executive Chairman, Editas Medicine; former president and CEO of Biogen; director at Thermo Fisher Scientific1

James C. “Jim” Mullen (born c. 1958) is an American business executive.2

From Wikipedia’s article on James Mullen (this version), CC BY-SA 4.0.

Born 1950.1

About

He is the executive chairman at genome editing company Editas Medicine since 2018, where he was CEO between 2021 and 2022. He was formerly the president and CEO of Biogen Idec until he retired effective June 8, 2010. At the same time, he started he would retire from the board at the end of his term. In 2011, he was named CEO to drug manufacturer Patheon, based in Durham, North Carolina, as well as to their board. He stayed there until August 29, 2017.

From Wikipedia’s article on James Mullen, shared under CC BY-SA 4.0.2

Companies

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

As of each latest filing. The line shows shares held over time.

Recent filings

Early life and education

  • Date not recordedRensselaer Polytechnic Institute3
  • Date not recordedVillanova University3

Mullen has a Bachelor of Science in chemical engineering from Rensselaer Polytechnic Institute and a Master of Business Administration from Villanova University. He has been a trustee at Villanova since 2001.

From Wikipedia’s article on James Mullen (this version), CC BY-SA 4.0.

Career

Occupation: business executive.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31